Nykode Therapeutics AS (NYKD.OL)
NOK 2.59
(15.42%)
NOK 2.59
(15.42%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -58.08 Million USD | -18.77% |
| 2022 | -505.32 Million USD | -516.74% |
| 2021 | -81.93 Million USD | -104.79% |
| 2020 | 1.7 Billion USD | 1477.26% |
| 2019 | -124.1 Million USD | -59.62% |
| 2018 | -77.75 Million NOK | -79.79% |
| 2017 | -43.24 Million NOK | -71.86% |
| 2016 | -25.16 Million NOK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -11.78 Million USD | 24.46% |
| 2024 Q1 | -166.27 Million USD | 9.01% |
| 2023 FY | -600.19 Million USD | -18.77% |
| 2023 Q2 | -129.02 Million USD | 14.82% |
| 2023 Q3 | -151.07 Million USD | -17.09% |
| 2023 Q4 | -186.91 Million USD | -23.72% |
| 2023 Q1 | -151.47 Million USD | 0.78% |
| 2022 Q2 | -99.58 Million NOK | -29.05% |
| 2022 FY | -505.32 Million USD | -516.74% |
| 2022 Q4 | -152.66 Million USD | 24.01% |
| 2022 Q3 | -200.89 Million NOK | -101.73% |
| 2022 Q1 | -77.16 Million NOK | -163.86% |
| 2021 Q4 | 120.83 Million NOK | 228.57% |
| 2021 FY | -81.93 Million USD | -104.79% |
| 2021 Q3 | -93.98 Million NOK | 0.0% |
| 2020 FY | 1.7 Billion USD | 1477.26% |
| 2019 FY | -124.1 Million USD | -59.62% |
| 2018 FY | -77.75 Million NOK | -79.79% |
| 2017 FY | -43.24 Million NOK | -71.86% |
| 2016 FY | -25.16 Million NOK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Arctic Bioscience AS | -48.58 Million NOK | -19.544% |
| Aqua Bio Technology ASA | -17.85 Million NOK | -225.259% |
| ArcticZymes Technologies ASA | 15.74 Million NOK | 468.868% |
| BerGenBio ASA | -191.81 Million NOK | 69.72% |
| Hofseth BioCare ASA | -102.52 Million NOK | 43.351% |
| PCI Biotech Holding ASA | -22.24 Million NOK | -161.148% |
| Thor Medical ASA | -7.16 Million NOK | -711.201% |
| Ultimovacs ASA | -215.73 Million NOK | 73.077% |